People · Operator
Named in public records as an officer, director or promoter · active 2014–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | — | Biotechnology | Series D+ | $569.0M | $2.4B | 2014 |
Frank Armstrong at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frank Armstrong on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeff Huber | 1 | 75 |
| Mostafa Ronaghi | 1 | 8 |
| David Wurzer | 1 | 7 |
| Robert Booth | 1 | 4 |
| Jim Mellon | 1 | 4 |
| Robert Duggan | 1 | 3 |
| Raymond Spencer | 1 | 3 |
| Mahkam Zanganeh | 1 | 3 |
| Kenneth Clark | 1 | 3 |
| David Roblin | 1 | 3 |
| Leopoldo Zambeletti | 1 | 2 |
| Barry Price | 1 | 2 |
| Manmeet Soni | 1 | 2 |
| Manmeet W. Soni | 1 | 1 |
| Daniel W. Elger | 1 | 1 |
| Ventzislav W. Stefanov | 1 | 1 |
| Valerie Andrews | 1 | 1 |
| Stephen Davies | 1 | 1 |
| Glyn Edwards | 1 | 1 |
| Alessandra Cesano | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.